Figure 4:

Brilacidin inhibits infection by pseudotyped SARS-CoV-2 variants including P.1 (Brazil strain) and B.1.1.7 (UK strain). Pseudotyped luciferase reporter viruses expressing spike protein from SARS-CoV-2 P.1 (A) or B1.1.7 (B) variants were incubated with various concentrations of brilacidin at 37°C for 1h before adding to HeLa-hACE2 cells for 2h. Cultures were continued, and luciferase activity was measured at 48h as described in Methods. Data represent mean ± SD of five replicates, and were analyzed by one-way ANOVA; *p < 0.05.